7 ACA Ramp-Up Plan
Target 80-100% utilization by end of first year of operation, with 80% for captive consumption and 20% for third-party sales once customer approvals are obtained from the new Jammu site.
ORCHPHARMA / guidance tracker
Keep management guidance in view.
Orchid Pharma · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
expansion
Se Pro Facility Commissioning
Facility target ready by December 2026, with first commercial batch expected in January-March 2027, subject to DCGI trial waiver approval which takes 6-9 months.
7 ACA Commercial Batch Target
First commercial batch targeting March 2027 from Jammu facility, representing 20x scale-up from existing pilot plant, with another 800x scale-up planned for full production.
WHO PQ Filing
Plan to file with WHO Geneva for Product Quality certification to enable simplified registrations across multiple countries, taking approximately two years for approval.
10-15% Revenue Growth for FY27 Base Business
Management targets 10-15% revenue growth for the core business in FY27, excluding new product contributions, resuming the historical trend disrupted by FY26 industry headwinds.
12% EBITDA Margin Target for FY27 Base Business
The company is targeting approximately 12% EBITDA margin for the base business in FY27, with continued focus on cost efficiency and operational improvements.
7ACA Project Commissioning Q1 CY27
The 7ACA project remains on track for commissioning in Q1 2027, with process technology being repeatedly validated at Chennai facility to ensure design parameters are fully stabilized.
Seprocal Launch Q2-Q3 CY27
Seprocal facility commissioning expected by end of CY26, subject to regulatory approvals and registrations, with product launch anticipated in Q2 or Q3 of CY27.